Back to top

Bristol gains accelerated approval of iberdomide for multiple myeloma

Bristol gains accelerated approval of iberdomide for multiple myeloma

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Bristol Myers Squibb Company (BMY)

Johnson & Johnson (JNJ)